^
    Back
    Association details:
    Biomarker:PDGFRA expression
    Cancer:Renal Cell Carcinoma
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    PLoS One
    Title:

    Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

    Excerpt:
    Immunostaining of HIF-1α, CA9, Ki67, CD31, pVEGFR1, VEGFR1 and -2, pPDGFRα and -β was significantly associated with the sunitinib response after 6 and 9 months as well as last report under therapy. Furthermore, HIF-1α, CA9, CD34, VEGFR1 and -3 and PDGRFα showed significant associations with progression-free survival (PFS) and overall survival (OS).
    DOI:
    10.1371/journal.pone.0076386